Valuation: Intra-Cellular Therapies, Inc.

Market Cap 1.4TCr 1.23TCr 1.13TCr 1.04TCr 1.96TCr 1,35000Cr 2.01TCr 14TCr 5.32TCr 66TCr 5.27TCr 5.15TCr 2,27700Cr P/E 2023
-49.2x
P/E 2024 -115x
Enterprise Value 1.3TCr 1.14TCr 1.05TCr 969.08Cr 1.83TCr 1,25600Cr 1.87TCr 13TCr 4.94TCr 61TCr 4.9TCr 4.79TCr 2,11700Cr EV / Sales 2023
13.8x
EV / Sales 2024 11.6x
Free-Float
95.68%
Yield 2023 *
-
Yield 2024 -
3 years 45.5
Extreme 45.5
131.98
5 years 28.4
Extreme 28.4
131.98
10 years 6.75
Extreme 6.75
131.98
Manager TitleAgeSince
Chief Tech/Sci/R&D Officer - 01/04/2022
Compliance Officer 64 02/07/2019
Corporate Secretary - -
Date Insider Type Main position Quantity % Market Cap.
02/04/25 Issuer saleCompany 10,000 0.0094%
02/04/25 Issuer sale

Director

52,606 0.0495%
02/04/25 Issuer sale

EVP, Chief Commercial Officer

1,67,824 0.1578%
Change 5-day change 1-year change 3-year change Capi.($)
-0.04%-.--%-.--%+109.18% 1.4TCr
-0.33%+1.83%+24.73%-5.89% 6.88TCr
+0.67%+0.93%+36.86%+194.41% 5.21TCr
+0.94%+39.60%+39.60%+39.60% 4.35TCr
-0.21%+1.42%-51.80%-53.61% 4.12TCr
-1.40%+3.43%+64.81%-25.61% 3.04TCr
-2.11%-9.45%+97.76%-50.61% 2.45TCr
+0.51%+0.46%+72.78%+86.41% 2.34TCr
+4.10%+3.70%+4.23%+195.68% 1.98TCr
-0.86%-1.99%+70.03%+124.61% 1.66TCr
Average +0.11%-0.52%+35.90%+61.42% 3.34TCr
Weighted average by Cap. +0.07%+0.08%+31.48%+49.95%

Financials

2023 2024
Net sales 46Cr 41Cr 37Cr 35Cr 65Cr 4.47TCr 67Cr 447.59Cr 176.05Cr 2.19TCr 174.39Cr 170.57Cr 7.54TCr 68Cr 59Cr 55Cr 51Cr 95Cr 6.56TCr 98Cr 656.25Cr 258.12Cr 3.21TCr 255.69Cr 250.08Cr 11TCr
Net income -14Cr -12Cr -11Cr -10Cr -20Cr -1.35TCr -20Cr -134.63Cr -53Cr -658.77Cr -52Cr -51Cr -2.27TCr -7.47Cr -6.53Cr -6.02Cr -5.55Cr -10Cr -719.14Cr -11Cr -72Cr -28Cr -352.21Cr -28Cr -27Cr -1.21TCr
Net Debt -48Cr -42Cr -39Cr -36Cr -67Cr -4.63TCr -69Cr -463.62Cr -182.35Cr -2.27TCr -180.64Cr -176.68Cr -7.81TCr -98Cr -86Cr -79Cr -73Cr -137.87Cr -9.48TCr -140.93Cr -948.52Cr -373.08Cr -4.64TCr -369.57Cr -361.46Cr -16TCr
Logo Intra-Cellular Therapies, Inc.
Intra-Cellular Therapies, Inc. is a biopharmaceutical company focused on the development and commercialization of small molecule drugs that address underserved medical needs primarily in psychiatric and neurological disorders. The Company’s product, CAPLYTA (lumateperone), is an oral, once daily atypical antipsychotic approved in adults for the treatment of schizophrenia and the treatment of depressive episodes associated with bipolar I or II disorder (bipolar depression) as monotherapy and as adjunctive therapy with lithium or valproate. Lumateperone is also being studied for the treatment of major depressive disorder, and other psychiatric and neurological disorders. Its pipeline includes several product candidates in clinical development and additional product candidates in non-clinical testing, such as the ITI-1284-ODT-SL program, Phosphodiesterase type I inhibitor (PDE1) program, ITI-333 program, and ITI-1500 Non-Hallucinogenic Psychedelic program.
Employees
860
Trader
-
Investor
-
Global
-
Quality
-
ESG MSCI
BBB
  1. Stock Market
  2. Stocks
  3. ITCI Stock